成立年份: 2023
总资产(USD): 不愿意公开
员工总人数: 10至19
主要竞争优势: 经验丰富的研发人员,发货速度,产品线丰富,接受小额订单,良好的信誉
其他竞争优势:
专利与版权:
业务类型: 制造商,分销商,贸易公司
年销售额(USD): 不愿意公开
主要销售市场: 西欧,东欧,亚洲
主要产品类别: 中间体
所有产品: Macitentan APl and IntermediateNew Mirogabalin APl and IntermediateNew Edoxaban APl and Intermediate Brigatinib APl and Intermediate Brexpiprazole APl and IntermediateNew R-lipoic acid APl and Intermediate ltraphylline APl and Intermediate Lifitegrast APl and Intermediate Upadacitinib APl and IntermediateNew Semaglutide APl and IntermediateNew Suvorexant APl and Intermediate Lemborexant APl and Intermediate Fosravuconazole APl and IntermediateNew Esaxerenone APl and IntermediateNew Alectinib APl and IntermediateNew Daprodustat APl and IntermediateNew Elobixibat APl and Intermediate lpragliflozin APl and Intermediate Fexuprazan APl and Intermediate Cenobamate APl and Intermediate
外销比重:
内销比重:
主要客户:
合同定制:
付款条款:
北京市朝阳区东三环南路25号16层1626室